Search Results - "Mfopou, Josué Kunjom"

  • Showing 1 - 9 results of 9
Refine Results
  1. 1

    Efficient definitive endoderm induction from mouse embryonic stem cell adherent cultures: A rapid screening model for differentiation studies by Mfopou, Josué Kunjom, Geeraerts, Marloes, Dejene, Roba, Van Langenhoven, Stijn, Aberkane, Asma, Van Grunsven, Leo A., Bouwens, Luc

    Published in Stem cell research (01-01-2014)
    “…Definitive endoderm (DE) differentiation from mouse embryonic stem cell (mESC) monolayer cultures has been limited by poor cell survival or low efficiency…”
    Get full text
    Journal Article
  2. 2

    Noggin, Retinoids, and Fibroblast Growth Factor Regulate Hepatic or Pancreatic Fate of Human Embryonic Stem Cells by Mfopou, Josué Kunjom, Chen, Bing, Mateizel, Ileana, Sermon, Karen, Bouwens, Luc

    Published in Gastroenterology (New York, N.Y. 1943) (01-06-2010)
    “…Background & Aims New sources of β cells are needed to develop cell therapies for patients with diabetes. An in vitro, sequential method has been developed to…”
    Get full text
    Journal Article
  3. 3

    Recent Advances and Prospects in the Differentiation of Pancreatic Cells From Human Embryonic Stem Cells by KUNJOM MFOPOU, Josué, BING CHEN, SUI, Lina, SERMON, Karen, BOUWENS, Luc

    Published in Diabetes (New York, N.Y.) (01-09-2010)
    “…Recent studies with human embryonic stem (hES) cells have established new protocols for substantial generation of pancreatic progenitors from definitive…”
    Get full text
    Journal Article
  4. 4
  5. 5

    Role of BMP Signaling in Pancreatic Progenitor Differentiation from Human Embryonic Stem Cells by Sui, Lina, Geens, Mieke, Sermon, Karen, Bouwens, Luc, Mfopou, Josué Kunjom

    Published in Stem cell reviews (01-10-2013)
    “…Transplantation of pancreatic progenitors derived from human embryonic stem cells (hESCs) is a promising way to treat diabetes. Strategies to obtain the…”
    Get full text
    Journal Article
  6. 6

    The Effect of Modafinil on the Safety and Pharmacokinetics of Lorlatinib: A Phase I Study in Healthy Participants by Li, Jerry, Pithavala, Yazdi K., Gong, Jason, LaBadie, Robert R., Mfopou, Josué Kunjom, Chen, Joseph

    Published in Clinical pharmacokinetics (01-10-2021)
    “…Background and Objective Lorlatinib is a third-generation tyrosine kinase inhibitor approved for the second-line treatment of patients with advanced anaplastic…”
    Get full text
    Journal Article
  7. 7

    Differentiation of pluripotent stem cells into pancreatic lineages by Mfopou, Josué Kunjom, Bouwens, Luc

    Published in M.S. Médecine sciences (01-08-2013)
    “…Diabetes mellitus is the leading metabolic disease and represents a major public health concern worldwide. Whereas the transplantation of pancreas…”
    Get more information
    Journal Article
  8. 8

    First-in-Human Phase 1a Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the Noncovalent Bruton Tyrosine Kinase (BTK) Inhibitor SNS-062 in Healthy Subjects by Neuman, Linda L., Ward, Renee, Arnold, David, Combs, Daniel L., Gruver, Deena, Hill, Wendy, Kunjom, Josué Mfopou, Miller, Langdon L., Fox, Judith A.

    Published in Blood (02-12-2016)
    “…Background: SNS-062 is a potent, noncovalent (reversible) BTK inhibitor in development for B-cell malignancies and other cancers. SNS-062 has the potential for…”
    Get full text
    Journal Article
  9. 9

    Recent advances and prospects in the differentiation of pancreatic cells from human embryonic stem cells.(PERSPECTIVES IN DIABETES) by Mfopou, Josue Kunjom, Chen, Bing, Sui, Lina, Sermon, Karen, Bouwens, Luc

    Published in Diabetes (New York, N.Y.) (01-09-2010)
    “…Recent studies with human embryonic stem (hES) cells have established new protocols for substantial generation of pancreatic progenitors from definitive…”
    Get full text
    Journal Article